Overview

Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients

Status:
Suspended

Trial end date:
2016-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether addition of AS101 to the standard chemotherapy regimen is effective in the treatment of newly diagnosed elderly (≥60) AML patients and AML transformed myelodysplastic syndrome (MDS) patients.

Phase:

Phase 2

Details

Lead Sponsor:

BioMAS Ltd

Treatments:

Ammonium trichloro(dioxoethylene-O,O'-)tellurate